SARS-CoV-2 (human) Neutralizing Recombinant Antibody

SARS-CoV-2 (human) Neutralizing Recombinant Antibody

CAT N°: 32526
Price:

513.00 436.05

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus, a member of the Betacoronavirus genus, and the causative agent of COVID-19.{53462,53459,53461,55257,55258} The SARS-CoV-2 surface glycoprotein, also known as the spike glycoprotein, is located on the outer envelope of the virion.{53462} It is composed of an S1 and S2 subunit divided by a furin S-cleavage site not found in other SARS-CoVs.{46767,49561} The S1 subunit contains the receptor-binding domain (RBD), which binds to the carboxypeptidase angiotensin-converting enzyme 2 (ACE2), and the S1 and S2 subunits are cleaved by the protease TMPRSS2 to facilitate viral fusion with the host cell membrane.{49542,49536,49558} In this way, ACE2 acts as the functional receptor for SARS-CoV-2. SARS-CoV-2 infection can result in the production of neutralizing antibodies, which bind to the SARS-CoV-2 spike RBD preventing further viral entry and infection, starting approximately 4-10 days after symptom onset.{55337,55338} Cayman’s SARS-CoV-2 (human) Neutralizing Recombinant Antibody disrupts the S1 RBD-ACE2 interaction and can be used for ELISA, immunofluorescence (IF), and Western blot (WB) applications. The antibody recognizes the SARS-CoV-2 spike glycoprotein at approximately 65 kDa.

We also advise you

TAF 10 Peptide

TAF 10 Peptide

TAF10 is one of many protein factors or coactivators associated with RNA polymerase II activity.{16903} One vial of this peptide...

€191.00
View